Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Everolimus dose-titration in pediatric relapsed or refractory Hodgkin lymphoma
2013-000256-18Phase 2Terminated
- Sponsor
- Novartis
- Start
- May 2013
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of everolimus in Hodgkin lymphoma (HL) and classical Hodgkin lymphoma (cHL), sponsored by Novartis. Primary endpoint: overall response rate. Started May 2013; status: terminated.
02
Drugs
everolimus
03
Conditions
Hodgkin lymphoma (HL)classical Hodgkin lymphoma (cHL)
Beyond the preview
Go deeper on 2013-000256-18.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2013-000256-18.